BioNTech (NASDAQ:BNTX) Price Target Lowered to $101.00 at UBS Group

BioNTech (NASDAQ:BNTX) had its price target trimmed by UBS Group from $110.00 to $101.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. lowered their target price on BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research note on Friday, March 22nd. BMO Capital Markets lowered their price target on shares of BioNTech from $127.00 to $123.00 and set an outperform rating for the company in a report on Thursday, March 21st. Canaccord Genuity Group reissued a buy rating and set a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. HC Wainwright dropped their target price on BioNTech from $133.00 to $107.00 and set a buy rating for the company in a research report on Tuesday, January 23rd. Finally, Oppenheimer began coverage on shares of BioNTech in a report on Friday, January 5th. They issued a market perform rating for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Hold and an average price target of $133.77.

BioNTech Stock Up 1.4 %

NASDAQ BNTX opened at $92.97 on Wednesday. BioNTech has a fifty-two week low of $85.21 and a fifty-two week high of $131.52. The business has a fifty day moving average price of $93.52 and a two-hundred day moving average price of $99.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The stock has a market capitalization of $22.10 billion, a PE ratio of 22.57 and a beta of 0.23.

Institutional Investors Weigh In On BioNTech

Several large investors have recently modified their holdings of the company. CWM LLC boosted its position in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares in the last quarter. State of Wyoming acquired a new stake in shares of BioNTech during the 2nd quarter worth approximately $26,000. Frazier Financial Advisors LLC acquired a new position in shares of BioNTech during the 4th quarter valued at $30,000. Covestor Ltd acquired a new stake in BioNTech in the third quarter worth $32,000. Finally, Eagle Bay Advisors LLC acquired a new position in BioNTech during the 2nd quarter worth approximately $33,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.